[Management of neuropathic bladder in multiple sclerosis].
It is estimated that almost 70% of patients affected by multiple sclerosis (MS) suffer from urinary symptoms, with devastant impact on Quality of Life (QoL). The major aims of management should be to ameliorate the patients quality of life and to prevent the frequent complications of bladder dysfunction such as infention and renal damage. Therapy can usually eliminate or reduce the symptoms of neuropathic bladder. In the following pages is discussed the complex management of urinary symptoms in MS patients.
Pappalardo
A
A
Centro Sclerosi Multipla, Azienda Policlinico, Università di Catania, Italia. pange.bel@virgilio.it
Patti
F
F
Reggio
A
A
D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000008:administration & dosage; D002211:Capsaicin / Q000008:administration & dosage / Q000627:therapeutic use; D003408:Cresols / Q000008:administration & dosage / Q000627:therapeutic use; D004224:Diterpenes / Q000008:administration & dosage / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications* / Q000503:physiopathology; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D010665:Phenylpropanolamine; D011379:Prognosis; D011788:Quality of Life; D013997:Time Factors; D000068737:Tolterodine Tartrate; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000534:rehabilitation / Q000601:surgery / Q000628:therapy*; D014563:Urodynamics
D000929:Antidepressive Agents, Tricyclic; D001559:Benzhydryl Compounds; D003408:Cresols; D004224:Diterpenes; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C024353:resiniferatoxin; D001905:Botulinum Toxins; D002211:Capsaicin